Prognosis
Cadila May Double Vaccine Capacity as Indian Cases Surge
- Company expects regulatory nod for its Covid vaccine by June
- Firm to boost Remdesivir production amid countrywide shortages
This article is for subscribers only.
Indian drugmaker Cadila Healthcare Ltd., which expects regulatory approval for its vaccine against Covid-19 by June, will potentially ramp up capacity to 240 million annual doses as the South Asian nation races to contain the world’s fastest-growing coronavirus outbreak.
Ahmedabad, Gujarat-based Cadila is expecting efficacy readings from its last stage of clinical trials in May, Sharvil Patel, the family-run firm’s managing director, said in an interview. If that data is promising, the drugmaker may double its vaccine making capabilities and is banking on a new local factory that will likely be commissioned next month, according to Patel.